Kimberly A Forde1,2, Michael B Fallon3, Michael J Krowka4, Michael Sprys2, David S Goldberg1,2, Karen L Krok5, Mamta Patel1,2, Grace Lin4, Jae K Oh4, Carl D Mottram4, Paul D Scanlon4, Steven M Kawut1,2. 1. Department of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 3. Department of Medicine, University of Arizona, Phoenix, AZ. 4. Department of Medicine, Mayo Clinic, Rochester, MN. 5. Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA.
Abstract
Screening for hepatopulmonary syndrome (HPS) using pulse oximetry is recommended in liver transplant (LT) candidates because mortality is increased, independently of the severity of the oxygenation defect. LT exception points may be afforded to those with HPS and severe hypoxemia. We assessed the screening characteristics of pulse oximetry for HPS. The Pulmonary Vascular Complications of Liver Disease 2 study is a multicenter, prospective cohort study of adults undergoing their first LT evaluation. Patients underwent protocolized assessment of oxygen saturation by pulse oximetry (SpO2 ), arterial blood gas, spirometry, and contrast-enhanced echocardiography (CE). HPS was defined as an alveolar-arterial gradient ≥15 mm Hg (≥20 mm Hg if age >64 years), intrapulmonary vascular dilatation on CE, and absence of lung disease. The study sample included 363 patients. Of these, 75 (20.7%; 95% confidence interval [CI], 16.6%-25.2%) met the criteria for HPS. The area under the receiver operating characteristic curve (or c-statistic) for SpO2 in discriminating HPS was 0.59 (95% CI, 0.51-0.66). An SpO2 <96%, recommended by practice guidelines as a threshold to require further testing, had low sensitivity (28%; 95% CI, 18%-28%). The c-statistic of SpO2 in discriminating HPS with a partial pressure of oxygen (PaO2 ) <60 mm Hg (eligible for LT exception points) was 0.76 (95% CI, 0.46-1.00). An SpO2 cutoff of <96% had higher sensitivity for detecting HPS with PaO2 <60 mm Hg (71%; 95% CI, 38%-100%) but was still inadequate. Conclusion: Pulse oximetry is not sufficiently sensitive to screen for HPS in LT candidates. Arterial blood gas and CE are required in LT candidates for diagnosis of HPS.
Screening for hepatopulmonary syndrome (HPS) using pulse oximetry is recommended in liver transplant (LT) candidates because mortality is increased, independently of the severity of the oxygenation defect. LT exception points may be afforded to those with HPS and severe hypoxemia. We assessed the screening characteristics of pulse oximetry for HPS. The Pulmonary Vascular Complications of Liver Disease 2 study is a multicenter, prospective cohort study of adults undergoing their first LT evaluation. Patients underwent protocolized assessment of oxygen saturation by pulse oximetry (SpO2 ), arterial blood gas, spirometry, and contrast-enhanced echocardiography (CE). HPS was defined as an alveolar-arterial gradient ≥15 mm Hg (≥20 mm Hg if age >64 years), intrapulmonary vascular dilatation on CE, and absence of lung disease. The study sample included 363 patients. Of these, 75 (20.7%; 95% confidence interval [CI], 16.6%-25.2%) met the criteria for HPS. The area under the receiver operating characteristic curve (or c-statistic) for SpO2 in discriminating HPS was 0.59 (95% CI, 0.51-0.66). An SpO2 <96%, recommended by practice guidelines as a threshold to require further testing, had low sensitivity (28%; 95% CI, 18%-28%). The c-statistic of SpO2 in discriminating HPS with a partial pressure of oxygen (PaO2 ) <60 mm Hg (eligible for LT exception points) was 0.76 (95% CI, 0.46-1.00). An SpO2 cutoff of <96% had higher sensitivity for detecting HPS with PaO2 <60 mm Hg (71%; 95% CI, 38%-100%) but was still inadequate. Conclusion: Pulse oximetry is not sufficiently sensitive to screen for HPS in LT candidates. Arterial blood gas and CE are required in LT candidates for diagnosis of HPS.
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Peter Schenk; Maximilian Schöniger-Hekele; Valentin Fuhrmann; Christian Madl; Gerd Silberhumer; Christian Müller Journal: Gastroenterology Date: 2003-10 Impact factor: 22.682
Authors: Michael J Krowka; M Susan Mandell; Michael A E Ramsay; Steve M Kawut; Michael B Fallon; Cosme Manzarbeitia; Manuel Pardo; Paul Marotta; Shinji Uemoto; Markus P Stoffel; Joanne T Benson Journal: Liver Transpl Date: 2004-02 Impact factor: 5.799
Authors: Elizabeth R Rochon; Michael J Krowka; Sonja Bartolome; Gustavo A Heresi; Todd Bull; Kari Roberts; Anna Hemnes; Kimberly A Forde; Karen L Krok; Mamta Patel; Grace Lin; Megan McNeil; Nadine Al-Naamani; Beth L Roman; Paul B Yu; Michael B Fallon; Mark T Gladwin; Steven M Kawut Journal: Am J Respir Crit Care Med Date: 2020-06-15 Impact factor: 21.405
Authors: Steven M Kawut; Susan S Ellenberg; Michael J Krowka; David Goldberg; Hugo Vargas; David Koch; Tiffany Sharkoski; Nadine Al-Naamani; Alyson Fox; Robert Brown; Joshua Levitsky; Jae K Oh; Grace Lin; Nianfu Song; Carl Mottram; Margaret F Doyle; David E Kaplan; Samir Gupta; Michael B Fallon Journal: Liver Transpl Date: 2019-05-30 Impact factor: 5.799
Authors: Hilary M DuBrock; Michael J Krowka; Karen Krok; Kimberly Forde; Carl Mottram; Paul Scanlon; Nadine Al-Naamani; Mamta Patel; Amber McCormick; Michael B Fallon; Steven M Kawut Journal: Liver Transpl Date: 2020-07-09 Impact factor: 5.799